Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16684570 | 1.00 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16693090 | 1.00 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL7811397 | 0.76 | CHRM1 (0.42) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL231364 | 0.76 | CHRM1 (0.42) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL231365 | 0.76 | CHRM1 (0.42) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16684597 | 0.76 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16693185 | 0.76 | CHRM3 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16684596 | 0.76 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL9040889 | 0.76 | CHRM1 (0.79) | CHRM1CHRM2CHRM3 | |
| SCHEMBL9040900 | 0.76 | CHRM1 (0.79) | CHRM1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-8304545-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8158784-B2 | Quinuclidine derivative useful in the preparation of mequitazine | PIERRE FABRE MEDICAMENT (FR) | 2012-04-17 | — | — | US | disclosed |
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | MIOSKOWSKI CHARLES (FR) | 2012-04-12 | — | — | US | disclosed |
| US-20100105897-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | PIERRE FABRE MEDICAMENT (FR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088917-A1 | NEW QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | AZI2, NQO2, SIRT5 | CHRM1 64/4885CHRM2 31/4885CHRM3 63/4885 |
| US-20100105897-A1 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE | AZI2, NQO2, SIRT5 | CHRM1 94/4885CHRM2 64/4885CHRM3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.